Eric Macklin

Featured in: Favicon

jamanetwork.com (+1) Favicon

karger.com Favicon

neurology.org Favicon

onlinelibrary.wiley.com Favicon

publications.aap.org

Articles

Prognostic Clinical and Biological Markers for Amyotrophic Lateral Sclerosis Disease Progression: Validation and Implications for Clinical Trial Design and Analysis

Aug 13, 2024 | medrxiv.org | Michael Benatar |Eric Macklin |Andrea Malaspina |Mary-Louise Rogers

MB reports grants from the NIH (U01NS107027, U54NS092091) and the ALS Association (16-TACL-242) in support of this work. He is also an unpaid member of the Board of Trustees for the ALS Association. He has served as a consultant to Alector, Alexion, Annexon, Arrowhead, Biogen, Cartesian, Denali, Eli Lilly, Horizon, Immunovant, Novartis, Roche, Sanofi, Takeda, UCB, and UniQure. EAM reports grants from the NIH (U01NS107027, U54NS092091).

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →